<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03558035</url>
  </required_header>
  <id_info>
    <org_study_id>LC2014L12</org_study_id>
    <nct_id>NCT03558035</nct_id>
  </id_info>
  <brief_title>New Strategy of Improving Treatment Outcome and Larynx-preservation Rate in Locally Advanced Hypopharyngeal Carcinoma</brief_title>
  <official_title>New Strategy of Improving Treatment Outcome and Larynx-preservation Rate in Locally Advanced Hypopharyngeal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To develope stratification treatment for the patients who have locally advanced&#xD;
      hypopharyngeal carcinoma. Experimental group patients were treated individually according to&#xD;
      the response status after induction chemotherapy, receiving chemoradiotherapy or surgery.&#xD;
      Thus to achieve a better survival rate and a higher larynx-preservation rate as well as a&#xD;
      lower treatment related toxicity rate compared with standard treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligiblity patient were assign to induction chemotherapy plus concurrent chemotherapy group&#xD;
      (IC +CCRT group, Arm A)and concurrent chemoradiotherapy group(CCRT group, Arm B). For&#xD;
      patients in Arm A, treatment response were evaluated after 2cycles, if the response reached&#xD;
      partial response/complete response, patients received concurrent chemoradiotherapy,&#xD;
      otherwise, patients will received surgery and radiotherpay/concurrent chemoradiotherapy after&#xD;
      surgery. For patients received concurrent chemoradiotherapy (both in Arm A and Arm B) ,&#xD;
      treatment response were evaluated at 50 Gy. if response reached complete response or major&#xD;
      partial response(&gt;80% tumor regression), patients will received radical chemoradiotherapy,&#xD;
      otherwise, patients will received surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>5 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>disease free survival</measure>
    <time_frame>5 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>distant-metastasis free survival</measure>
    <time_frame>5 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>larynx-preservation rate</measure>
    <time_frame>5 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>treatment related toxicities</measure>
    <time_frame>2 year</time_frame>
    <description>hematology and surgery related complications</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Hypopharyngeal Cancer</condition>
  <arm_group>
    <arm_group_label>Induction chemotherapy and concurret chemoradiotherapy group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive 2 cycles of paclitaxel, cisplatin and 5-Fluorouracil chemotherapy followed by Surgery or Chemo-radiotherapy according to the response status after induction chemo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Concurrent chemoradiotherapy group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive single-agent cisplatin chemotherapy concurrent with Radiotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Induction CT+ CRT group</intervention_name>
    <description>Induction CT: Paclitaxel 175mg/m2 IV on d1 and d22, cisplatin 75mg/m2 IV on d1 and d22, 5-Fluorouracil 750mg/m2 IV continuously on d1-4 and d22-25, CRT: cisplatin 80mg/m2 IV on d1 of each 21 days cycle and 70 Gy radiotherapy</description>
    <arm_group_label>Induction chemotherapy and concurret chemoradiotherapy group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Concurrent CRT group</intervention_name>
    <description>cisplatin 100mg/m2 IV on d1 of each 21 days cycle and 70 Gy radiotherapy</description>
    <arm_group_label>Concurrent chemoradiotherapy group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically proven squamous cell carcinoma of hypopharynx&#xD;
&#xD;
          -  Stage III/IV M0, with T3/4 N0-3 or T1-4 N2-3&#xD;
&#xD;
          -  Karnofsky Performance Status&gt;=70&#xD;
&#xD;
          -  Have measurable lesions on CT/MRI&#xD;
&#xD;
          -  Treatment for the first time&#xD;
&#xD;
          -  Expected lifetime &gt; 6 months&#xD;
&#xD;
          -  Normal blood test, hepatic and renal functions&#xD;
&#xD;
          -  Normal hearing&#xD;
&#xD;
          -  Can understand and sign the consent&#xD;
&#xD;
          -  Have follow up condition&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Past malignancies history (except for stage I non-melanoma skin cancer or cervical&#xD;
             carcinoma in situ)&#xD;
&#xD;
          -  Previously treatment for cancer&#xD;
&#xD;
          -  Pregnant or breeding woman, female without contraception&#xD;
&#xD;
          -  Enrolling in other drug trials&#xD;
&#xD;
          -  Severe comorbidities including myocardial infarction, arrhythmia, cerebral vascular&#xD;
             disease, ulceration disease, mental disease and uncontrolled diabetes&#xD;
&#xD;
          -  Without follow up&#xD;
&#xD;
          -  Receive target therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Junlin Yi, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>CAMS</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Junlin Yi, Professor</last_name>
    <phone>0086013661217998</phone>
    <email>yijunlin1969@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cancer hospital, Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Junlin YI, MD</last_name>
      <phone>861087788504</phone>
      <email>junlinyi@sohu.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Blanchard P, Baujat B, Holostenco V, Bourredjem A, Baey C, Bourhis J, Pignon JP; MACH-CH Collaborative group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): a comprehensive analysis by tumour site. Radiother Oncol. 2011 Jul;100(1):33-40. doi: 10.1016/j.radonc.2011.05.036. Epub 2011 Jun 16.</citation>
    <PMID>21684027</PMID>
  </reference>
  <reference>
    <citation>Blanchard P, Bourhis J, Lacas B, Posner MR, Vermorken JB, Cruz Hernandez JJ, Bourredjem A, Calais G, Paccagnella A, Hitt R, Pignon JP; Meta-Analysis of Chemotherapy in Head and Neck Cancer, Induction Project, Collaborative Group. Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group. J Clin Oncol. 2013 Aug 10;31(23):2854-60. doi: 10.1200/JCO.2012.47.7802. Epub 2013 Jul 8.</citation>
    <PMID>23835714</PMID>
  </reference>
  <reference>
    <citation>Pointreau Y, Garaud P, Chapet S, Sire C, Tuchais C, Tortochaux J, Faivre S, Guerrif S, Alfonsi M, Calais G. Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. J Natl Cancer Inst. 2009 Apr 1;101(7):498-506. doi: 10.1093/jnci/djp007. Epub 2009 Mar 24.</citation>
    <PMID>19318632</PMID>
  </reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>June 5, 2018</study_first_submitted>
  <study_first_submitted_qc>June 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 15, 2018</study_first_posted>
  <last_update_submitted>January 28, 2021</last_update_submitted>
  <last_update_submitted_qc>January 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Jun-Lin Yi, MD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Hypopharyngeal carcinoma</keyword>
  <keyword>Locally advanced</keyword>
  <keyword>Multi-disciplinary treatment</keyword>
  <keyword>Functional Magnetic Resonance Imaging</keyword>
  <keyword>Prognosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Hypopharyngeal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

